You are here

FDA Approves Octagam 10% for Immune Thrombocytopenic Purpura

Product expected to be available in September

The FDA has approved Octagam 10% (immune globulin intravenous [human] 10% [100 mg/mL] liquid preparation, Octapharma USA) for the treatment of adults with chronic immune thrombocytopenic purpura (ITP), a platelet disorder that can result in easy or excessive bruising and bleeding.

Since 2004, Octagam 5% (immune globulin intravenous [human] 5% [50 mg/mL] liquid preparation) has been marketed for the treatment of primary humoral immunodeficiency.

Octagam 10% is expected to be available in the U.S. in September 2014.

The FDA’s approval was based on the results of a clinical trial that evaluated the safety and efficacy of Octagam 10% in 66 patients (aged 17 to 88 years) with chronic ITP.

The study — published in the October 2010 issue of Hematology — found that 82% of patients with chronic ITP had attained the primary efficacy endpoint of a clinical response (i.e., platelet count ≥ 50 × 109/L within 7 days of dosing), which was significantly higher than the predicted responder rate of 70%. There were no unexpected tolerability issues even at the maximum infusion rate of 0.12 mL/kg/minute (720 mg/kg/hour). Further, 78% of patients with chronic ITP who had bleeding at baseline reported no bleeding 7 days after treatment.

The most common treatment-related adverse events associated with Octagam 10% included headache, fever, and increased heart rate. The most serious adverse event was a moderate headache.

Octagam 10% is indicated for the treatment of chronic ITP in adults to rapidly increase platelet counts to control or prevent bleeding. Octagam 10% is a solvent/detergent-treated, sterile preparation of highly purified immunoglobulin G derived from large pools of human plasma. The product is a solution for infusion to be administered intravenously.

The labelling for Octagam 10% includes a boxed warning regarding the potential for thrombosis, renal dysfunction, and acute renal failure.

Sources: Octapharma USA; July 15, 2014; and Octagam 10% Prescribing Information; July 2014.

Recent Headlines

Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention
More research is needed to confirm the finding
A new 'road map' might make it easier
Rationing, canceled treatments, and fearful patients